Guilin Sanjin Pharmaceutical Co., Ltd.

002275

CNE100000DY9

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
14.3 ^CNY	+0.92%		-5.17%	-1.31%

Apr. 26	Guilin Sanjin Pharmaceutical Co., Ltd. Proposes Final Dividend for 2023	CI
Apr. 25	Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Guilin Sanjin Pharmaceutical Co., Ltd.(XSEC:002275) added to S&P Global BMI Index

September 18, 2023 at 12:00 am EDT

Latest news about Guilin Sanjin Pharmaceutical Co., Ltd.

Guilin Sanjin Pharmaceutical Co., Ltd. Proposes Final Dividend for 2023	Apr. 26	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 04	CI
Guilin Sanjin Pharma to Sell Land, Buildings For 111 Million Yuan	Dec. 28	MT
Guilin Sanjin Pharmaceutical Co., Ltd. Implements Profit Distribution plan for the Third Quarter of 2023, Payable on 27 November 2023	Nov. 21	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Approves 2023 Third Quarter Profit Distribution Plan	Nov. 15	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Proposes Third Quarter Dividend for 2023	23-10-30	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-29	CI
Guilin Sanjin Pharmaceutical Co., Ltd.(XSEC:002275) added to S&P Global BMI Index	23-09-18	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-24	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on May 31, 2023	23-05-24	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Approves Cash Dividend for 2022	23-05-22	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-26	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-27	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Approves Board Elections	22-12-27	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Approves Dividend for the Third Quarter of 2022	22-11-15	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Announces the Profit Distribution Proposal for the Third Quarter of 2022	22-10-31	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-28	CI
Biocytogen Pharmaceuticals Raises $60 Million in RemeGen-Backed Hong Kong IPO	22-08-31	MT
Biocytogen Pharmaceuticals Launches $70 Million Hong Kong IPO	22-08-19	MT
Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-18	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Approves Cash Dividend for 2021, Payable on 30 May 2022	22-05-24	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Approves Cash Dividend for 2021	22-05-19	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for 2021	22-04-27	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-26	CI

Chart Guilin Sanjin Pharmaceutical Co., Ltd.

Duration

Period

Chart Guilin Sanjin Pharmaceutical Co., Ltd.

More charts

Guilin Sanjin Pharmaceutical Co., Ltd is a China-based company, principally engaged in the research, production and distribution of Chinese patent medicines, as well as distribution of products. The Company's main products portfolio consists of watermelon frost series, including watermelon frost lozenge, guilin watermelon frost and watermelon frost throat lozenge, mainly used for treatment of throat and mouth diseases; sanjin tablets, mainly used for treatment of urinary system infection, as well as naomaitai capsules, mainly used for treatment of cardiovascular and cerebrovascular diseases. It distributes its products within domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

2024-05-16 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Guilin Sanjin Pharmaceutical Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

14.3

Average target price

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Alternative Medicine

	1st Jan change	Capi.
GUILIN SANJIN PHARMACEUTICAL CO., LTD.	-1.31%	1.16B
DONG-E-E-JIAO CO.,LTD.	+39.33%	6.11B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-18.38%	4.35B
TASLY PHARMACEUTICAL GROUP CO., LTD	-9.17%	3.18B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+3.98%	3.15B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-3.41%	2.51B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+48.74%	1.98B
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-4.82%	1.74B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	-1.24%	1.63B
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-8.96%	1.6B

Alternative Medicine